Sai Life Sciences Limited announced impressive financial results for the second quarter of FY2025, reporting a revenue from operations of ₹66,058 crore. The figures were disclosed on November 8, 2025, following the approval of the results in a board meeting held on November 6. This revenue reflects a significant increase compared to the previous quarter, where the company reported ₹64,232 crore. The growth in revenue signals a robust performance in the biopharmaceutical sector, highlighting Sai Life Sciences' strong position in the market.

In terms of profitability, the company recorded a profit before tax of ₹6,540 crore for the quarter, compared to ₹5,676 crore in Q1 FY2025. The net profit for the period stood at ₹4,741 crore, showcasing a rise from ₹4,004 crore in the prior quarter. The earnings per share were also notable, with basic earnings of ₹21.35 and diluted earnings of ₹21.32 per share. This substantial growth in profits underscores the effectiveness of Sai Life Sciences' operational strategies and market demand for its services.

The detailed financial results are available on the BSE and NSE websites, as well as on Sai Life Sciences' official site. This transparency aligns with the company's commitment to adhering to the SEBI Listing Obligations and Disclosure Requirements. As Sai Life Sciences continues to expand its operations and enhance profitability, stakeholders will be keen to monitor the company’s performance in the upcoming quarters, especially in light of the ongoing developments in the pharmaceutical industry.